Cargando…
Cytocompatibility Evaluation of a Novel Series of PEG-Functionalized Lactide-Caprolactone Copolymer Biomaterials for Cardiovascular Applications
Although the use of bioresorbable materials in stent production is thought to improve long-term safety compared to their durable counterparts, a recent FDA report on the 2-year follow-up of the first FDA-approved bioresorbable vascular stent showed an increased occurrence of major adverse cardiac ev...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7438451/ https://www.ncbi.nlm.nih.gov/pubmed/32903548 http://dx.doi.org/10.3389/fbioe.2020.00991 |
_version_ | 1783572795563704320 |
---|---|
author | Pacharra, Sandra McMahon, Seán Duffy, Patrick Basnett, Pooja Yu, Wenfa Seisel, Sabine Stervbo, Ulrik Babel, Nina Roy, Ipsita Viebahn, Richard Wang, Wenxin Salber, Jochen |
author_facet | Pacharra, Sandra McMahon, Seán Duffy, Patrick Basnett, Pooja Yu, Wenfa Seisel, Sabine Stervbo, Ulrik Babel, Nina Roy, Ipsita Viebahn, Richard Wang, Wenxin Salber, Jochen |
author_sort | Pacharra, Sandra |
collection | PubMed |
description | Although the use of bioresorbable materials in stent production is thought to improve long-term safety compared to their durable counterparts, a recent FDA report on the 2-year follow-up of the first FDA-approved bioresorbable vascular stent showed an increased occurrence of major adverse cardiac events and thrombosis in comparison to the metallic control. In order to overcome the issues of first generation bioresorbable polymers, a series of polyethylene glycol-functionalized poly-L-lactide-co-ε-caprolactone copolymers with varying lactide-to-caprolactone content is developed using a novel one-step PEG-functionalization and copolymerization strategy. This approach represents a new facile way toward surface enhancement for cellular interaction, which is shown by screening these materials regarding their cyto- and hemocompatibility in terms of cytotoxicity, hemolysis, platelet adhesion, leucocyte activation and endothelial cell adhesion. By varying the lactide-to-caprolactone polymer composition, it is possible to gradually affect endothelial and platelet adhesion which allows fine-tuning of the biological response based on polymer chemistry. All polymers developed were non-cytotoxic, had acceptable leucocyte activation levels and presented non-hemolytic (<2% hemolysis rate) behavior except for PLCL-PEG 55:45 which presented hemolysis rate of 2.5% ± 0.5. Water contact angles were reduced in the polymers containing PEG functionalization (PLLA-PEG: 69.8° ± 2.3, PCL-PEG: 61.2° ± 7.5) versus those without (PLLA: 79.5° ± 3.2, PCL: 76.4° ± 10.2) while the materials PCL-PEG550, PLCL-PEG550 90:10 and PLCL-PEG550 70:30 demonstrated best endothelial cell adhesion. PLLA-PEG550 and PLCL-PEG550 70:30 presented as best candidates for cardiovascular implant use from a cytocompatibility perspective across the spectrum of testing completed. Altogether, these polymers are excellent innovative materials suited for an application in stent manufacture due to the ease in translation of this one-step synthesis strategy to device production and their excellent in vitro cyto- and hemocompatibility. |
format | Online Article Text |
id | pubmed-7438451 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-74384512020-09-03 Cytocompatibility Evaluation of a Novel Series of PEG-Functionalized Lactide-Caprolactone Copolymer Biomaterials for Cardiovascular Applications Pacharra, Sandra McMahon, Seán Duffy, Patrick Basnett, Pooja Yu, Wenfa Seisel, Sabine Stervbo, Ulrik Babel, Nina Roy, Ipsita Viebahn, Richard Wang, Wenxin Salber, Jochen Front Bioeng Biotechnol Bioengineering and Biotechnology Although the use of bioresorbable materials in stent production is thought to improve long-term safety compared to their durable counterparts, a recent FDA report on the 2-year follow-up of the first FDA-approved bioresorbable vascular stent showed an increased occurrence of major adverse cardiac events and thrombosis in comparison to the metallic control. In order to overcome the issues of first generation bioresorbable polymers, a series of polyethylene glycol-functionalized poly-L-lactide-co-ε-caprolactone copolymers with varying lactide-to-caprolactone content is developed using a novel one-step PEG-functionalization and copolymerization strategy. This approach represents a new facile way toward surface enhancement for cellular interaction, which is shown by screening these materials regarding their cyto- and hemocompatibility in terms of cytotoxicity, hemolysis, platelet adhesion, leucocyte activation and endothelial cell adhesion. By varying the lactide-to-caprolactone polymer composition, it is possible to gradually affect endothelial and platelet adhesion which allows fine-tuning of the biological response based on polymer chemistry. All polymers developed were non-cytotoxic, had acceptable leucocyte activation levels and presented non-hemolytic (<2% hemolysis rate) behavior except for PLCL-PEG 55:45 which presented hemolysis rate of 2.5% ± 0.5. Water contact angles were reduced in the polymers containing PEG functionalization (PLLA-PEG: 69.8° ± 2.3, PCL-PEG: 61.2° ± 7.5) versus those without (PLLA: 79.5° ± 3.2, PCL: 76.4° ± 10.2) while the materials PCL-PEG550, PLCL-PEG550 90:10 and PLCL-PEG550 70:30 demonstrated best endothelial cell adhesion. PLLA-PEG550 and PLCL-PEG550 70:30 presented as best candidates for cardiovascular implant use from a cytocompatibility perspective across the spectrum of testing completed. Altogether, these polymers are excellent innovative materials suited for an application in stent manufacture due to the ease in translation of this one-step synthesis strategy to device production and their excellent in vitro cyto- and hemocompatibility. Frontiers Media S.A. 2020-08-13 /pmc/articles/PMC7438451/ /pubmed/32903548 http://dx.doi.org/10.3389/fbioe.2020.00991 Text en Copyright © 2020 Pacharra, McMahon, Duffy, Basnett, Yu, Seisel, Stervbo, Babel, Roy, Viebahn, Wang and Salber. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Bioengineering and Biotechnology Pacharra, Sandra McMahon, Seán Duffy, Patrick Basnett, Pooja Yu, Wenfa Seisel, Sabine Stervbo, Ulrik Babel, Nina Roy, Ipsita Viebahn, Richard Wang, Wenxin Salber, Jochen Cytocompatibility Evaluation of a Novel Series of PEG-Functionalized Lactide-Caprolactone Copolymer Biomaterials for Cardiovascular Applications |
title | Cytocompatibility Evaluation of a Novel Series of PEG-Functionalized Lactide-Caprolactone Copolymer Biomaterials for Cardiovascular Applications |
title_full | Cytocompatibility Evaluation of a Novel Series of PEG-Functionalized Lactide-Caprolactone Copolymer Biomaterials for Cardiovascular Applications |
title_fullStr | Cytocompatibility Evaluation of a Novel Series of PEG-Functionalized Lactide-Caprolactone Copolymer Biomaterials for Cardiovascular Applications |
title_full_unstemmed | Cytocompatibility Evaluation of a Novel Series of PEG-Functionalized Lactide-Caprolactone Copolymer Biomaterials for Cardiovascular Applications |
title_short | Cytocompatibility Evaluation of a Novel Series of PEG-Functionalized Lactide-Caprolactone Copolymer Biomaterials for Cardiovascular Applications |
title_sort | cytocompatibility evaluation of a novel series of peg-functionalized lactide-caprolactone copolymer biomaterials for cardiovascular applications |
topic | Bioengineering and Biotechnology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7438451/ https://www.ncbi.nlm.nih.gov/pubmed/32903548 http://dx.doi.org/10.3389/fbioe.2020.00991 |
work_keys_str_mv | AT pacharrasandra cytocompatibilityevaluationofanovelseriesofpegfunctionalizedlactidecaprolactonecopolymerbiomaterialsforcardiovascularapplications AT mcmahonsean cytocompatibilityevaluationofanovelseriesofpegfunctionalizedlactidecaprolactonecopolymerbiomaterialsforcardiovascularapplications AT duffypatrick cytocompatibilityevaluationofanovelseriesofpegfunctionalizedlactidecaprolactonecopolymerbiomaterialsforcardiovascularapplications AT basnettpooja cytocompatibilityevaluationofanovelseriesofpegfunctionalizedlactidecaprolactonecopolymerbiomaterialsforcardiovascularapplications AT yuwenfa cytocompatibilityevaluationofanovelseriesofpegfunctionalizedlactidecaprolactonecopolymerbiomaterialsforcardiovascularapplications AT seiselsabine cytocompatibilityevaluationofanovelseriesofpegfunctionalizedlactidecaprolactonecopolymerbiomaterialsforcardiovascularapplications AT stervboulrik cytocompatibilityevaluationofanovelseriesofpegfunctionalizedlactidecaprolactonecopolymerbiomaterialsforcardiovascularapplications AT babelnina cytocompatibilityevaluationofanovelseriesofpegfunctionalizedlactidecaprolactonecopolymerbiomaterialsforcardiovascularapplications AT royipsita cytocompatibilityevaluationofanovelseriesofpegfunctionalizedlactidecaprolactonecopolymerbiomaterialsforcardiovascularapplications AT viebahnrichard cytocompatibilityevaluationofanovelseriesofpegfunctionalizedlactidecaprolactonecopolymerbiomaterialsforcardiovascularapplications AT wangwenxin cytocompatibilityevaluationofanovelseriesofpegfunctionalizedlactidecaprolactonecopolymerbiomaterialsforcardiovascularapplications AT salberjochen cytocompatibilityevaluationofanovelseriesofpegfunctionalizedlactidecaprolactonecopolymerbiomaterialsforcardiovascularapplications |